Research2 min read
CJC-1295 & Ipamorelin Stacking Protocols: Synergistic GH Pulse Optimization in Research
Laboratory research protocols for CJC-1295 and Ipamorelin combination studies. Review synergistic somatotropic signaling.
By PX1 Research Team · September 13, 2026
Dual Secretagogue Synergy
Co-administration of a GHRH analogue (CJC-1295 No DAC) with a selective ghrelin/growth hormone secretagogue receptor agonist (Ipamorelin) produces synergistic amplification of growth hormone output while minimizing receptor desensitization.
Buy Research-Grade CJC-1295 & Ipamorelin Blends
Most-researched PX1 compounds
- Buy PX13-R online99%+ HPLC PX13-R, lot-matched COA, 10mg / 20mg / 30mg / 40mg vials.View page
- GHK-Cu copper peptide for saleCopper tripeptide-1, 50mg and 100mg research vials, US cGMP synthesised.View page
- Research tesamorelin peptideTesamorelin 10mg and 20mg, growth-hormone-releasing factor analogue.View page
- CJC-1295 no DAC + ipamorelin blendPre-blended secretagogue research pairing, 10mg and 20mg presentations.View page
- Buy AOD-9604 peptideModified hGH fragment 176-191, lyophilised research vials with public COA.View page
- KLOW blend peptide for saleKPV, LL-37, GHK-Cu and BPC-157 five-peptide research blend, 80mg total.View page
PX1 Research Team
PX1 Research is a primary US cGMP-compliant peptide manufacturer. Our team handles solid-phase synthesis, HPLC purification, lyophilization and in-house analytical testing — every batch ships with a lot-specific Certificate of Analysis.
See how we manufactureAll PX1 Research products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption.